Ticagrelor
Back to searchMolecule Structure
Scientific Name
Ticagrelor
Description of the Drug
Ticagrelor is a P2Y12 platelet inhibitor used in patients with a history of myocardial infarction or with acute coronary syndrome (ACS) to prevent future myocardial infarction, stroke and cardiovascular death.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB08816
http://www.drugbank.ca/drugs/DB08816
Brand Name(s)
Brilinta, Brilique
Company Owner(s)
Hisun Pharmaceutical Hangzhou Co Ltd, Sunshine Lake Pharma Co Ltd, Sigmapharm Laboratories Llc, Astrazeneca Pharmaceuticals Lp, Watson Laboratories Inc, Mylan Pharmaceuticals Inc, Amneal Eu Ltd
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Purinergic receptor P2Y12 | SINGLE PROTEIN | NEGATIVE ALLOSTERIC MODULATOR | CHEMBL2001 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL1979652 | |
PharmGKB | PA165374673 | |
Human Metabolome Database | HMDB0015702 | |
DrugBank | DB08816 | |
PubChem: Thomson Pharma | 14860737 | 14836432 |
PubChem | 9871419 | |
Nikkaji | J1.905.358J | |
PDBe | TIQ | |
BindingDB | 50397205 | |
DrugCentral | 4184 | |
ChemicalBook | CB51509134 | |
Guide to Pharmacology | 1765 | |
rxnorm | BRILINTA | TICAGRELOR |
PubChem: Drugs of the Future | 49684205 | |
ChEBI | 68558 | |
ZINC | ZINC000028957444 |